跳到主要导航 跳到搜索 跳到主要内容

Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study

  • Xianlong Zhou
  • , Haifeng Hou
  • , Luyu Yang
  • , Guoyong Ding
  • , Tao Wei
  • , Cancan Li
  • , Yuanyuan Heng
  • , Ruining Liu
  • , Min Ma
  • , Zhuanzhuan Hu
  • , Lei Huang
  • , Xizhu Xu
  • , Quan Hu
  • , Yan Zhao
  • , Weijia Xing*
  • , Zhigang Zhao*
  • *此作品的通讯作者
  • Shandong First Med Univ
  • Shandong Acad Med Sci
  • Binzhou Med Univ
  • Wuhan Third Hosp
  • Huazhong Univ Sci & Technol
  • First Peoples Hosp Jiangxia Dist

科研成果: 期刊稿件 › 论文 › 同行评审

10 引用 (Scopus)

摘要

["Background The antiviral therapy has been considered as an ordinary intervention for COVID-19 patients. However, the effectiveness of antiviral therapy is uncertain. This study was designed to determine the association between the antiviral therapy and in-hospital mortality among severe COVID-19 patients.","Methods This study enrolled severe COVID-19 patients admitted to four designated hospitals in Wuhan, China. The use of antiviral treatments, demographics, laboratory variables, co-morbidities, complications, and other treatments were compared between survival and fatal cases. The association between antiviral agents and in-hospital mortality were analyzed.","Results In total, 109 severe COVID-19 patients (mean age 65.43) were enrolled for analysis, among which, 61 (56.0%) patients were discharged alive, and 48 (44.0%) died during hospitalization. We found no association between lopinavir/ritonavir (LPV/r) treatment and the in-hospital mortality (odds ratio (OR) = 0.195, 95% confidence interval (CI) = 0.023-1.679). Besides, ribavirin (OR = 0.738, 95% CI = 0.344-1.582), oseltamivir (OR = 0.765, 95% CI = 0.349-1.636), and interferon-alpha (IFN-a) (OR = 0.371, 95% CI = 0.112-1.236) were not associated with the in-hospital mortality. However, arbidol monotherapy (OR = 5.027, 95% CI = 1.79514.074) or the combination of arbidol and oseltamivir (OR = 5.900, 95% CI =1.190-29.247) was associated with an increased in-hospital mortality. In addition, the multiple logistic regression identified a significant association between the use of arbidol and the in-hospital mortality (adjusted OR = 4.195, 95% CI = 1.221-14.408).","Conclusions Our findings indicated that LPV/r, IFN-a, ribavirin, or oseltamivir have no beneficial effects on the prognosis of severe COVID-19 patients, whereas the use of arbidol is associated with increased in-hospital mortality."]
源语言英语
期刊论文编号05017
页数8
期刊Journal of Global Health
卷11
DOI
出版状态已出版 - 1月 2021

基金资助

This study was supported by Natural Science Foundation of Shandong Province, China (ZR2017MH100), the Academic Promotion Program of Shandong First Medical University (No. 2019RC010), the Young Taishan Scholars Program of Shandong Province of China (No. tsqn20161046), and Shandong Province Higher Educational Young and Innovation Technology Supporting Program (No. 2019KJL004).

收录

  • SCIE
  • SSCI

学术指纹

探究 'Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study' 的科研主题。它们共同构成独一无二的学术指纹。

引用此